HOME >> BIOLOGY >> NEWS
Finding the right recipe: Researchers tailor magnetic nanoparticles for medical treatment & diagnosis

Nanoparticles that possess magnetic properties offer exciting new opportunities for delivering drugs to targeted areas in the body, replacing radioactive tracer materials, improving the quality of noninvasive medical imaging, and producing ever-smaller data storage devices. But before these magnetic nanoparticles gain widespread use, scientists must learn to consistently control their key properties.

Using only variations in chemistry and process conditions, researchers at the Georgia Institute of Technology have learned to precisely control the size and magnetic properties of one class of magnetic nanoparticles. Their goal is a "recipe book" other researchers could use to produce nanoparticles with exactly the right properties for different applications.

"If you are going to produce these nanoparticles for large-scale use, you cannot guess at the conditions or rely on intuition," said Dr. John Zhang, Georgia Tech assistant professor of chemistry and biochemistry. "We are understanding the fundamental ways to control the properties of these particles, chemically manipulating the magnetic interactions at the atomic level. We want to control these properties through chemical means."

Zhang will present his research team's latest findings at the 219th national meeting of the American Chemical Society March 26, 2000 in San Francisco. The team includes Adam J. Rondinone, Anna C.S. Samia, Chao Liu, and Richard Anderson.

Because each potential application for the magnetic nanoparticles requires different properties, the work is essential to their future use as carriers of drugs, tracers and MRI contrast enhancement agents. Also, it will provide insights to some key technical issues in high density information storage.

For instance, each particle possesses certain magnetic orientations just as the north or sout
'"/>

Contact: John Toon
john.toon@edi.gatech.edu
404-894-6986
Georgia Institute of Technology Research News
26-Mar-2000


Page: 1 2 3 4

Related biology news :

1. Findings suggest need for new view of p53 cancer proteins interaction with DNA
2. Finding the hole in the defenses of cavity-creating microbes
3. Findings redefine mechanism of action of RNA helicase enzymes
4. Findings of novel nanoproperties in selenium produced by bacteria open new area of exploration
5. Finding may help eczema sufferers tolerate smallpox vaccine
6. Findings could aid efforts to harness nature for making drugs
7. Findings offer clue to how molecule can both stimulate, suppress cell growth
8. Findings offer further understanding about growth and development in young male gymnasts
9. Findings in frog oocytes may help study of chromosome physiology
10. Finding dirty bombs and other radiation threats
11. Finding life away from Earth will be tough task, says noted paleontologist

Post Your Comments:
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: